SG11201900814QA - Viral vaccines - Google Patents
Viral vaccinesInfo
- Publication number
- SG11201900814QA SG11201900814QA SG11201900814QA SG11201900814QA SG11201900814QA SG 11201900814Q A SG11201900814Q A SG 11201900814QA SG 11201900814Q A SG11201900814Q A SG 11201900814QA SG 11201900814Q A SG11201900814Q A SG 11201900814QA SG 11201900814Q A SG11201900814Q A SG 11201900814QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- victoria
- pct
- chikungunya
- zika virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 February 2018 (22.02.2018) WIP0 I PCT o mum I 1000 1111001010 IMOD EEO 011 (10) International Publication Number WO 2018/032057 Al (51) International Patent Classification: A61K 35/76 (2015.01) A61P 31/12 (2006.01) A61K 31/7088 (2006.01) (21) International Application Number: PCT/AU2017/050879 (22) International Filing Date: 18 August 2017 (18.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016903295 19 August 2016 (19.08.2016) AU (71) Applicant: SEMENTIS LIMITED [AU/AU]; 9 Sing Crescent, Berwick, Victoria 3806 (AU). (72) Inventor: HOWLEY, Paul; 9 Sing Crescent, Berwick, Victoria 3806 (AU). (74) Agent: DAVIES COLLISON CAVE PTY LTD; 1 Nicholson Street, Melbourne, Victoria 3000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) N O M (54) Title: VIRAL VACCINES (57) : The present invention relates to a composition for raising an immune response in animal which decreases the risk of chikungunya and smallpox infection, Zika virus and smallpox infection, and/or chikungunya, Zika virus and smallpox infection. The 0 composition comprises a pharmaceutically acceptable carrier and an attenuated poxvirus, wherein the poxvirus genome comprises a N nucleic acid sequence encoding the 26S subgenomic polyprotein of chikungunya virus and/or the PrME of Zika virus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016903295A AU2016903295A0 (en) | 2016-08-19 | Viral Vaccines | |
PCT/AU2017/050879 WO2018032057A1 (en) | 2016-08-19 | 2017-08-18 | Viral vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900814QA true SG11201900814QA (en) | 2019-03-28 |
Family
ID=61195904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900814QA SG11201900814QA (en) | 2016-08-19 | 2017-08-18 | Viral vaccines |
Country Status (17)
Country | Link |
---|---|
US (2) | US10905759B2 (en) |
EP (2) | EP3500280A4 (en) |
JP (1) | JP2019528271A (en) |
KR (1) | KR20190050787A (en) |
CN (1) | CN109862909A (en) |
AR (1) | AR110624A1 (en) |
AU (1) | AU2017313450B2 (en) |
BR (1) | BR112019003181A2 (en) |
CA (1) | CA3034282A1 (en) |
CL (1) | CL2019000405A1 (en) |
IL (1) | IL264893B (en) |
MA (1) | MA45994A (en) |
MX (1) | MX2019001919A (en) |
NZ (1) | NZ750578A (en) |
SG (1) | SG11201900814QA (en) |
TW (1) | TWI728173B (en) |
WO (1) | WO2018032057A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210299245A1 (en) * | 2020-03-31 | 2021-09-30 | Sementis Limited | Attenuated poxvirus vector based vaccine for protection against covid-19 |
CN112362877B (en) * | 2020-10-27 | 2024-04-12 | 江苏先声医学诊断有限公司 | MBP recombinant protein and application thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3911010B2 (en) * | 1994-04-29 | 2007-05-09 | イムノ・アクテイエンゲゼルシヤフト | Recombinant poxvirus having a foreign polynucleotide in the essential region |
CN1418951A (en) | 2001-05-23 | 2003-05-21 | 广州绿健生物技术有限公司 | Production for RNA virus and RNA virus based carrier granular composition and productive method thereof |
WO2003097846A1 (en) * | 2002-05-16 | 2003-11-27 | Bavarian Nordic A/S | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
EP2269619A1 (en) * | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Methods and compositions concerning poxviruses and cancer |
KR20040015624A (en) | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | Oral injectable pharmaceutical composition comprising florfenicol as active ingredient |
DK1594970T3 (en) * | 2003-02-18 | 2008-11-17 | Helmholtz Zentrum Muenchen | Method for Generating Recombinant MVA |
EP1518932A1 (en) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
EP1683870A1 (en) * | 2005-01-24 | 2006-07-26 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vaccines based on the use of MVA |
GB201006405D0 (en) * | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
EP2618840A2 (en) * | 2010-09-23 | 2013-07-31 | Baxter International Inc. | Recombinant viral vectors and methods for inducing an immune response to yellow fever virus |
CN105163756A (en) * | 2013-03-15 | 2015-12-16 | 赛门蒂斯有限公司 | Immune modulation |
CN106255758B (en) * | 2013-11-01 | 2020-06-23 | 赛门蒂斯有限公司 | Viral vector production |
WO2016086980A1 (en) * | 2014-12-02 | 2016-06-09 | Consejo Superior De Investigaciones Cientificas | Vaccine composition |
BR112018015696A2 (en) * | 2016-02-03 | 2018-12-26 | Geovax Inc | compositions and methods for generating an immune response to a flavivirus |
-
2017
- 2017-08-18 IL IL264893A patent/IL264893B/en unknown
- 2017-08-18 MX MX2019001919A patent/MX2019001919A/en unknown
- 2017-08-18 TW TW106128111A patent/TWI728173B/en active
- 2017-08-18 SG SG11201900814QA patent/SG11201900814QA/en unknown
- 2017-08-18 AU AU2017313450A patent/AU2017313450B2/en active Active
- 2017-08-18 AR ARP170102311A patent/AR110624A1/en unknown
- 2017-08-18 CA CA3034282A patent/CA3034282A1/en active Pending
- 2017-08-18 WO PCT/AU2017/050879 patent/WO2018032057A1/en active Search and Examination
- 2017-08-18 EP EP17840633.6A patent/EP3500280A4/en not_active Withdrawn
- 2017-08-18 US US16/325,539 patent/US10905759B2/en active Active
- 2017-08-18 EP EP23215911.1A patent/EP4331676A3/en active Pending
- 2017-08-18 MA MA045994A patent/MA45994A/en unknown
- 2017-08-18 KR KR1020197007662A patent/KR20190050787A/en not_active Application Discontinuation
- 2017-08-18 JP JP2019508842A patent/JP2019528271A/en active Pending
- 2017-08-18 BR BR112019003181A patent/BR112019003181A2/en active Search and Examination
- 2017-08-18 NZ NZ750578A patent/NZ750578A/en unknown
- 2017-08-18 CN CN201780063830.0A patent/CN109862909A/en active Pending
-
2019
- 2019-02-14 CL CL2019000405A patent/CL2019000405A1/en unknown
-
2020
- 2020-12-22 US US17/130,165 patent/US20210113684A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2017313450B2 (en) | 2024-02-15 |
MX2019001919A (en) | 2019-09-04 |
BR112019003181A2 (en) | 2019-07-16 |
TW201809273A (en) | 2018-03-16 |
IL264893A (en) | 2019-04-30 |
NZ750578A (en) | 2023-05-26 |
TWI728173B (en) | 2021-05-21 |
WO2018032057A1 (en) | 2018-02-22 |
AU2017313450A1 (en) | 2019-02-28 |
CN109862909A (en) | 2019-06-07 |
IL264893B (en) | 2022-08-01 |
CL2019000405A1 (en) | 2019-06-14 |
KR20190050787A (en) | 2019-05-13 |
CA3034282A1 (en) | 2018-02-22 |
EP4331676A3 (en) | 2024-05-15 |
JP2019528271A (en) | 2019-10-10 |
EP4331676A2 (en) | 2024-03-06 |
US20210113684A1 (en) | 2021-04-22 |
US10905759B2 (en) | 2021-02-02 |
US20200009245A1 (en) | 2020-01-09 |
RU2019107582A (en) | 2020-09-21 |
MA45994A (en) | 2021-03-17 |
AR110624A1 (en) | 2019-04-17 |
EP3500280A4 (en) | 2020-05-13 |
EP3500280A1 (en) | 2019-06-26 |
RU2019107582A3 (en) | 2021-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201805120YA (en) | Zika virus vaccine | |
SG11201910101SA (en) | Alphavirus neoantigen vectors | |
SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201811600PA (en) | Pseudotyped oncolytic viral delivery of therapeutic polypeptides | |
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11201805835WA (en) | Modified oncolytic virus | |
SG11201909572QA (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
SG11201811370XA (en) | A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
SG11201808709VA (en) | T cell receptors | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201803951QA (en) | Oligonucleotides for inducing paternal ube3a expression | |
SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
SG11202000312UA (en) | Encapsulated polynucleotides and methods of use |